Deadline: 12-Jan-2026
The European Partnership for Personalised Medicine, EP PerMed supported by the European Union under Horizon Europe, has launched its first research, innovation and technology call (RITC2026) for proposals on “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine”, acronym “MultiPMData2026”.
The recent call for projects aims to foster collaboration between enterprises and clinical actors—such as healthcare providers, patients, and researchers—to test innovative solutions for managing multimorbidity in real-world settings. Multimorbidity refers to patients living with at least two chronic diseases requiring ongoing management, such as cardiovascular, metabolic, respiratory, neurological, immunological, gastrointestinal, uro-genital conditions, cancer, or mental health disorders.
This initiative encourages projects focused on the use of multimodal data within personalized medicine approaches to improve the efficiency and personalization of care for patients with complex health needs. Key project goals include better detection and characterization of co-existing chronic diseases, improved diagnosis and monitoring of disease progression, and supporting a shift from in-patient to out-patient care through remote monitoring technologies like wearables.
The project duration can be up to a maximum of 36 months. Within the scope of the project, the contribution requested from TÜBİTAK excludes the Institutional Share and Project Incentive Bonus (PTI) and is subject to specific funding limits. The total funding per project may not exceed 220,000 Euros.
For each executing organization, there are additional limits based on the type of institution and their role in the international project consortium. Higher education institutions, training and research hospitals, and public institutions can receive up to 125,000 Euros if they are coordinating an international project. If they are participating as partners in such a consortium, the maximum funding is 100,000 Euros. For private organizations, the total amount requested cannot exceed 220,000 Euros.
Funding is available to a broad range of participants including for-profit enterprises of any size, clinical partners from public or private healthcare settings, academic and research institutions, as well as private non-profit organizations. However, to be eligible, projects must be transnational, involving at least three partners from three different EU Member States or Associated Countries, each eligible for funding from their respective organizations.
Participating countries in this call include Belgium (Flanders), Belgium (Wallonie), Czech Republic, Finland, France, Ireland, Israel, Italy, Latvia, Lithuania, Portugal (Centro Region), Romania, Slovak Republic, South Africa, Spain (Andalusia), Spain (Navarre), Sweden, Turkiye.
Importantly, each project consortium must include at least one enterprise partner and one clinical partner, ensuring collaboration between industry and healthcare practitioners. The project coordinator must also be eligible for funding in their region and cannot be changed during the application process.
This call represents a valuable opportunity to accelerate innovative approaches in managing multimorbidity by bridging the gap between technology, clinical expertise, and patient care across Europe.
For more information, visit TUBITAK.
